Cargando…
A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy
Ocular neovascularisation underlies blinding eye diseases such as retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related macular degeneration. These diseases cause irreversible vision loss, and provide a significant health and economic burden. Biologics targeting vascula...
Autores principales: | Sulaiman, Rania S., Merrigan, Stephanie, Quigley, Judith, Qi, Xiaoping, Lee, Bit, Boulton, Michael E., Kennedy, Breandán, Seo, Seung-Yong, Corson, Timothy W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857741/ https://www.ncbi.nlm.nih.gov/pubmed/27148944 http://dx.doi.org/10.1038/srep25509 |
Ejemplares similares
-
Ferrochelatase is a therapeutic target for ocular neovascularization
por: Basavarajappa, Halesha D, et al.
Publicado: (2017) -
Synergise or perish
por: Grover, Harpreet Singh
Publicado: (2021) -
Calcitriol and non-calcemic vitamin D analogue, 22-oxacalcitriol, attenuate developmental and pathological choroidal vasculature angiogenesis ex vivo and in vivo
por: Merrigan, Stephanie L., et al.
Publicado: (2020) -
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
por: Singerman, L J, et al.
Publicado: (2008) -
VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo
por: Rennel, E S, et al.
Publicado: (2009)